Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant ...

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

Avalyn Pharma is led by CEO Lyn Baranowski, who previously worked at Pearl Therapeutics, where she helped develop treatments ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...